Quick Answer
Methylfolate Mood Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Introduction Emerging real-world evidence suggests that folate supplementation may reduce suicidal ideation and behavior.
Key Takeaways
- 01Introduction Emerging real-world evidence suggests that folate supplementation may reduce suicidal ideation and behavior. [Noel C (2026)]
- 02One within-person cohort study found a 44% lower hazard of suicide-related emergency or hospital visits after treatment with folic acid (hazard ratio = 0.56) (and none in a parallel analysis of vitamin B12). [Noel C (2026)]
- 03One case-control study of patients with a history of suicidal behavior and ideation found lower suicidal ideation questionnaire scores with folinic acid ( P Discussion Evidence linking folate supplementation to reduced suicidal behavior is promising but limited by heterogeneity in design, sample size, folate formulation, and outcome measurement. [Noel C (2026)]
- 04We conducted a scoping review to evaluate current hypothesis-testing literature on folate supplementation and outcomes related to suicide. [Noel C (2026)]
The current Migaku evidence database contains 2 reusable source documents for Methylfolate Mood Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Introduction Emerging real-world evidence suggests that folate supplementation may reduce suicidal ideation and behavior. [Noel C (2026); evidence level 3]
- One within-person cohort study found a 44% lower hazard of suicide-related emergency or hospital visits after treatment with folic acid (hazard ratio = 0.56) (and none in a parallel analysis of vitamin B12). [Noel C (2026); evidence level 3]
- One case-control study of patients with a history of suicidal behavior and ideation found lower suicidal ideation questionnaire scores with folinic acid ( P Discussion Evidence linking folate supplementation to reduced suicidal behavior is promising but limited by heterogeneity in design, sample size, folate formulation, and outcome measurement. [Noel C (2026); evidence level 3]
- We conducted a scoping review to evaluate current hypothesis-testing literature on folate supplementation and outcomes related to suicide. [Noel C (2026); evidence level 3]
- A comprehensive review of psychiatric presentations reported that psychiatric symptoms span attention problems, anxiety, mood/behavioral disorders, and psychosis and identified > 100 IEMs associated with psychiatric manifestations; in a curated analysis, 94 IEMs were linked to psychiatric symptoms, with mood changes ranging from depressive syndromes to bipolar-like presentations []. [Hachmeriyan Antoniya (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources